Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s macroglobulinemia (WM). Ibrutinib, acalabrutinib,...
Saved in:
Main Authors: | Maroun Bou Zerdan, Jason Valent, Maria Julia Diacovo, Karl Theil, Chakra P. Chaulagain |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2022/1182384 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
by: Benjamin M. Heyman, et al.
Published: (2025-02-01) -
Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom’s Macroglobulinemia
by: Aasems Jacob, et al.
Published: (2017-01-01) -
Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom’s Macroglobulinemia
by: D. Kazmierski, et al.
Published: (2017-01-01) -
CNS Vasculitis Associated with Waldenström Macroglobulinemia
by: Tanawan Riangwiwat, et al.
Published: (2016-01-01) -
Focal Segmental Glomerulosclerosis in Waldenström’s Macroglobulinemia
by: Akshee Batra, et al.
Published: (2020-01-01)